Denosumab has become one of the most widely supplied biologics in India for bone health management, spanning two very different clinical worlds — osteoporosis prevention and cancer-related bone protection. For hospitals, pharmacies, and procurement teams, the practical challenge is rarely about treatment decisions, which always rest with the prescribing physician
Goserelin, sold under the brand name Zoladex, has been a cornerstone of hormone therapy for more than three decades, and it remains one of the most consistently prescribed LHRH agonists across Indian oncology and gynaecology practices in 2026. Despite how established the molecule is, hospital pharmacists and procurement teams still
In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states. Weeks earlier
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication
